Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition
US10058543B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 1, 2015 |
| Grant date | Aug 28, 2018 |
| Priority date | — |
| Expiry date | Jun 1, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0051
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.